• +1-646-491-9876
    • +91-20-67278686

    Search

    Merkel Cell Carcinoma Pipeline Review H1 2017

    Merkel Cell Carcinoma Pipeline Review H1 2017

    • Report Code ID: RW0001858653
    • Category Pharmaceuticals
    • No. of Pages 257
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Merkel Cell Carcinoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2017, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

    Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs) . Treatment includes chemotherapy, radiation therapy and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 9, 9 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

    Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Merkel Cell Carcinoma - Overview
    Merkel Cell Carcinoma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Merkel Cell Carcinoma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Merkel Cell Carcinoma - Companies Involved in Therapeutics Development
    Amgen Inc
    Apcure SAS
    BeiGene (Beijing) Co Ltd
    Bristol-Myers Squibb Company
    F. Hoffmann-La Roche Ltd
    Immune Design Corp
    Merck & Co Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    NantKwest Inc
    Novartis AG
    OncoSec Medical Inc
    Oncovir Inc
    Ono Pharmaceutical Co Ltd
    Philogen SpA
    Tarveda Therapeutics Inc
    Merkel Cell Carcinoma - Drug Profiles
    APC-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    atezolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    avelumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bevacizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BGBA-317 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy 1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy 2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    G-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ipilimumab + nivolumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MAL-3101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nivolumab - Drug Profile
    R&D Progress
    pasireotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pasireotide ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pazopanib hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pembrolizumab - Drug Profile
    R&D Progress
    PEN-221 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Poly-ICLC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sapanisertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    talimogene laherparepvec - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tavokinogene telseplasmid - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Teleukin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tigilanol tiglate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target WT1 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Merkel Cell Carcinoma - Product Development Milestones
    Featured News & Press Releases
    May 31, 2017: Triple therapy for rare skin cancer shows promise in small, early-stage trial
    May 17, 2017: Merck and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
    Mar 29, 2017: BAVENCIO (avelumab) Approved for the Treatment of Metastatic Merkel Cell Carcinoma, Available for Order at Biologics
    Mar 23, 2017: FDA Grants Approval for BAVENCIO (avelumab) , the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
    Mar 20, 2017: NantKwest Announces FDA Grant of Orphan Drug Designation for the Company's aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
    Mar 01, 2017: Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017
    Nov 29, 2016: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
    Nov 14, 2016: NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
    Oct 31, 2016: European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
    Sep 28, 2016: Merck to Present Data on Avelumab at ESMO 2016
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Merkel Cell Carcinoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Merkel Cell Carcinoma - Pipeline by Amgen Inc, H1 2017
    Merkel Cell Carcinoma - Pipeline by Apcure SAS, H1 2017
    Merkel Cell Carcinoma - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
    Merkel Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Merkel Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Merkel Cell Carcinoma - Pipeline by Immune Design Corp, H1 2017
    Merkel Cell Carcinoma - Pipeline by Merck & Co Inc, H1 2017
    Merkel Cell Carcinoma - Pipeline by Merck KGaA, H1 2017
    Merkel Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Merkel Cell Carcinoma - Pipeline by NantKwest Inc, H1 2017
    Merkel Cell Carcinoma - Pipeline by Novartis AG, H1 2017
    Merkel Cell Carcinoma - Pipeline by OncoSec Medical Inc, H1 2017
    Merkel Cell Carcinoma - Pipeline by Oncovir Inc, H1 2017
    Merkel Cell Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Merkel Cell Carcinoma - Pipeline by Philogen SpA, H1 2017
    Merkel Cell Carcinoma - Pipeline by Tarveda Therapeutics Inc, H1 2017

    List of Figures

    Number of Products under Development for Merkel Cell Carcinoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Amgen Inc
    Apcure SAS
    BeiGene (Beijing) Co Ltd
    Bristol-Myers Squibb Company
    F. Hoffmann-La Roche Ltd
    Immune Design Corp
    Merck & Co Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    NantKwest Inc
    Novartis AG
    OncoSec Medical Inc
    Oncovir Inc
    Ono Pharmaceutical Co Ltd
    Philogen SpA
    Tarveda Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//merkel-cell-carcinoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//merkel-cell-carcinoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//merkel-cell-carcinoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments